Savant Capital LLC Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Savant Capital LLC acquired a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 93,984 shares of the biotechnology company’s stock, valued at approximately $130,000. Savant Capital LLC owned approximately 0.08% of Coherus BioSciences as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of CHRS. Los Angeles Capital Management LLC increased its stake in shares of Coherus BioSciences by 344.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock valued at $967,000 after acquiring an additional 720,672 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Coherus BioSciences by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 964,327 shares of the biotechnology company’s stock valued at $1,003,000 after acquiring an additional 116,217 shares in the last quarter. FMR LLC increased its stake in shares of Coherus BioSciences by 21.1% in the 3rd quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 39,204 shares in the last quarter. Systematic Financial Management LP bought a new stake in Coherus BioSciences during the 3rd quarter valued at $28,000. Finally, XTX Topco Ltd increased its stake in Coherus BioSciences by 74.5% during the 3rd quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company’s stock valued at $492,000 after purchasing an additional 202,084 shares in the last quarter. Institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Price Performance

CHRS opened at $1.10 on Thursday. The company has a market capitalization of $127.48 million, a price-to-earnings ratio of -13.75 and a beta of 0.81. The firm’s fifty day moving average price is $1.36 and its two-hundred day moving average price is $1.21. Coherus BioSciences, Inc. has a 1 year low of $0.66 and a 1 year high of $2.78.

Analysts Set New Price Targets

A number of brokerages have commented on CHRS. Robert W. Baird boosted their price target on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Coherus BioSciences in a research note on Thursday, January 23rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.38.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.